Follicular Lymphoma
📧 Sign up to get email alerts when something new happens for Follicular Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2023-02-09Clinical Trial Update: Vincristine Sulfate Liposome Injection (Marqibo®), Bendamustine and Rituximab-Phase I Trial in Indolent B-cell Lymphoma [Phase 1]
Phase I trial evaluating a combination of Vincristine Sulfate Liposome Injection with Bendamustine and Rituximab in indolent B-cell lymphoma…
-
CLINICAL_TRIALS trial_result · 2023-01-20Clinical Trial Update: Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell Transplant [Phase 2]
Phase 2 trial evaluating ibrutinib in patients with refractory or relapsed lymphoma after donor stem cell transplant completed; results post…
-
CLINICAL_TRIALS trial_result · 2023-01-10Clinical Trial Update: Follicular Lymphoma IV/SC Rituximab Therapy (FLIRT) [Phase 3]
Phase 3 trial update for Follicular Lymphoma evaluating IV/SC Rituximab therapy (FLIRT) has completed.
-
CLINICAL_TRIALS trial_result · 2023-01-10Clinical Trial Update: Evaluation of Atezolizumab-Venetoclax-Obinutuzumab Combination in Relapse/Refractory Lymphomas [Phase 2]
Phase 2 clinical trial evaluating the atezolizumab-venetoclax-obinutuzumab combination in relapse/refractory lymphomas has completed enrollm…
-
CLINICAL_TRIALS trial_result · 2022-12-30Clinical Trial Update: Pembrolizumab in Untreated B-Cell Non-Hodgkin Lymphoproliferative Diseases [Phase 2]
A Phase 2 pembrolizumab trial in untreated B-cell non-Hodgkin lymphoproliferative diseases has been terminated; results have been posted.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2022-11-18Clinical Trial Update: Radiotherapy Versus Radiotherapy Plus Chemotherapy in Early Stage Follicular Lymphoma [Phase 3]
Phase 3 trial comparing radiotherapy alone versus radiotherapy plus chemotherapy in early-stage follicular lymphoma completed.
-
CLINICAL_TRIALS trial_result · 2022-11-17Clinical Trial Update: Lenalidomide, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large Cell or Follicular B-Cell Lymphoma [Phase 1, Phase 2]
A completed Phase 1/2 clinical trial evaluated lenalidomide and rituximab in combination with chemotherapy for newly diagnosed diffuse large…
-
CLINICAL_TRIALS trial_result · 2022-11-14Clinical Trial Update: A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Participants With Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma [Phase 1, Phase 2]
Phase 1/2 study of polatuzumab vedotin in combination with rituximab or obinutuzumab plus bendamustine in relapsed/refractory follicular lym…
-
CLINICAL_TRIALS trial_result · 2022-07-22Clinical Trial Update: Efficacy and Safety of Tisagenlecleucel in Adult Patients With Refractory or Relapsed Follicular Lymphoma [Phase 2]
Phase 2 trial evaluating the efficacy and safety of Kymriah (tisagenlecleucel) in adults with refractory or relapsed follicular lymphoma; re…
-
CLINICAL_TRIALS trial_result · 2022-07-21Clinical Trial Update: Study to Assess the Efficacy and Safety of Ublituximab + Umbralisib With or Without Bendamustine and Umbralisib Alone in Patients With Previously Treated Non-Hodgkins Lymphoma [Phase 2, Phase 3]
Phase 2/3 trial assessing ublituximab + umbralisib with or without bendamustine, and umbralisib alone, in previously treated non-Hodgkin lym…
-
CLINICAL_TRIALS trial_result · 2022-07-18Clinical Trial Update: Phase II Venetoclax, Obinutuzumab and Bendamustine in High Tumor Burden Follicular Lymphoma as Front Line Therapy [Phase 2]
Phase II trial evaluating frontline triplet therapy with venetoclax, obinutuzumab, and bendamustine in patients with high tumor burden folli…
-
CLINICAL_TRIALS trial_result · 2022-06-21Clinical Trial Update: "MIRO" Molecularly Oriented Immuno-radio-therapy [Phase 2]
Phase 2 trial update for MIRO molecularly oriented immuno-radio-therapy in follicular lymphoma patients has completed recruitment.
-
CLINICAL_TRIALS trial_result · 2022-05-06Clinical Trial Update: ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies [Phase 1, Phase 2]
Phase 1/2 trial of acalabrutinib (ACP-196) in combination with pembrolizumab in hematologic malignancies has completed with results posted i…
-
CLINICAL_TRIALS trial_result · 2022-04-22Clinical Trial Update: Rituximab, Fludarabine, Mitoxantrone, Dexamethasone (R-FND) Plus Zevalin for High-Risk Follicular Lymphoma [Phase 2]
Phase 2 trial evaluating R-FND chemotherapy plus Zevalin for high-risk follicular lymphoma has completed with posted results.
-
CLINICAL_TRIALS trial_result · 2022-04-05Clinical Trial Update: Phase 1/2a Dose Escalation Study in Participants With CLL, SLL, or NHL [Phase 1, Phase 2]
Phase 1/2a dose-escalation study in CLL/SLL and various NHL subtypes completed with results posted.
-
CLINICAL_TRIALS trial_result · 2022-02-10Clinical Trial Update: A Study of INCB050465 in Relapsed or Refractory Follicular Lymphoma [Phase 2]
Phase 2 study of INCB050465 in relapsed or refractory follicular lymphoma has completed, with results posted. The sponsor is Incyte Corporat…
-
CLINICAL_TRIALS trial_result · 2022-01-14Clinical Trial Update: Phase 3 Study of Zevalin Following R-CVP in Previously Untreated Patients With Follicular Non Hodgkin's Lymphoma (NHL) [Phase 3]
Phase 3 trial update for Zevalin after R-CVP in previously untreated follicular lymphoma; study status terminated with results posted.
-
CLINICAL_TRIALS trial_result · 2021-12-21Clinical Trial Update: Genetically Engineered Lymphocyte Therapy After Peripheral Blood Stem Cell Transplant in Treating Patients With High-Risk, Intermediate-Grade, B-cell Non-Hodgkin Lymphoma [Phase 1, Phase 2]
A phase 1/2 clinical trial investigates a genetically engineered lymphocyte therapy given after peripheral blood stem cell transplant in pat…
-
CLINICAL_TRIALS trial_result · 2021-12-16Clinical Trial Update: Study of Zevalin Versus Observation in Participants at Least 60 Years Old With Newly Diagnosed Diffuse Large B-cell Lymphoma in Positron Emission Tomography (PET)-Negative Complete Remission After Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) or R-CHOP-like Therapy [Phase 3]
Phase 3 trial evaluating Zevalin vs observation in older patients with newly diagnosed DLBCL achieving PET-negative complete remission after…
-
CLINICAL_TRIALS trial_result · 2021-11-19Clinical Trial Update: Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant [Phase 3]
Phase 3 trial comparing pixantrone + rituximab versus gemcitabine + rituximab in aggressive B-cell non-Hodgkin lymphoma and follicular grade…
-
CLINICAL_TRIALS trial_result · 2021-11-04Clinical Trial Update: A Phase II Trial of Combined Weekly Bortezomib and Tositumomab I-131 in Patients With Relapsed or Refractory Follicular Non-Hodgkin's Lymphoma [Phase 2]
Phase II trial evaluating weekly bortezomib with Tositumomab and I-131 in relapsed or refractory follicular non-Hodgkin's lymphoma has termi…
-
CLINICAL_TRIALS trial_result · 2021-10-28Clinical Trial Update: BTK Inhibitor BGB-3111 in Chinese Participants With Diffuse Large B-Cell Lymphoma (Non-GCB) and Indolent Lymphoma (FL and MZL) [Phase 2]
Phase 2 study of zanubrutinib (BGB-3111) in Chinese participants with Diffuse Large B-Cell Lymphoma (non-GCB) and indolent lymphomas (Follic…
-
CLINICAL_TRIALS trial_result · 2021-10-26Clinical Trial Update: Safety and Antitumor Activity Study of Loncastuximab Tesirine and Durvalumab in Diffuse Large B-Cell, Mantle Cell, or Follicular Lymphoma [Phase 1]
Phase 1 trial evaluating loncastuximab tesirine with durvalumab in various B-cell lymphomas was terminated; results posted in 2021.
-
CLINICAL_TRIALS trial_result · 2021-09-29Clinical Trial Update: Lenalidomide in Combination With Rituximab in Treating Participants With Stage III/IV Indolent Non-Hodgkin Lymphoma [Phase 2]
Phase 2 trial evaluating lenalidomide in combination with rituximab for various stage III/IV indolent non-Hodgkin lymphoma subtypes; study c…
-
CLINICAL_TRIALS trial_result · 2021-09-14Clinical Trial Update: A Study of TAK-659 as a Single Agent in Adult East Asian Participants With Non-Hodgkin Lymphoma (NHL) [Phase 1]
Phase 1 trial of TAK-659 as a single agent in adult East Asian participants with various non-Hodgkin lymphoma subtypes was terminated.